MedTrace Logo

Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis

NCT02704338 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-03-10

No results posted yet for this study

Summary

Separated and expanded the CD4+CD25+CD127- Tregs from peripheral blood of autoimmune hepatitis patients and administrate the cells (5 x 106 cells/kg) into patients.

Conditions

Interventions

BIOLOGICAL

Regulatory T cells

Regulatory t cells will be injected back to autoimmune hepatitis patients

Sponsors & Collaborators

  • Nanjing Medical University

    lead OTHER

Principal Investigators

  • Hong Wang, M.D.,PH.D. · Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-03-31
Completion
2018-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704338 on ClinicalTrials.gov